HSR23-108: Physician Preferences on Biomarker Testing in Newly-Diagnosed Metastatic NSCLC Patients Who Had Insufficient Tumor Tissue

Authors:
Anne ShahAstraZeneca, Gaithersburg, MD

Search for other papers by Anne Shah in
Current site
Google Scholar
PubMedClose
 PhD
,
Jon AppleAstraZeneca, Gaithersburg, MD

Search for other papers by Jon Apple in
Current site
Google Scholar
PubMedClose
 PharmD
,
Gabriela BurgosCerner Enviza, an Oracle Company, Kansas City, MO

Search for other papers by Gabriela Burgos in
Current site
Google Scholar
PubMedClose
 MPH
,
Josh LankinCerner Enviza, an Oracle Company, Kansas City, MO

Search for other papers by Josh Lankin in
Current site
Google Scholar
PubMedClose
 MSc
,
Jesse CohnCerner Enviza, an Oracle Company, Kansas City, MO

Search for other papers by Jesse Cohn in
Current site
Google Scholar
PubMedClose
 PhD
,
Janelle Cambron-MellottCerner Enviza, an Oracle Company, Kansas City, MO

Search for other papers by Janelle Cambron-Mellott in
Current site
Google Scholar
PubMedClose
 PhD
, and
Emily MulvihillCerner Enviza, an Oracle Company, Kansas City, MO

Search for other papers by Emily Mulvihill in
Current site
Google Scholar
PubMedClose
 MBA
View More View Less
Volume/Issue:
Volume 21: Issue 3.5
Online Publication Date:
31 Mar 2023
DOI:
https://doi.org/10.6004/jnccn.2022.7190
Restricted access

Corresponding Author: Anne Shah, PhD

Email: anne.shah@astrazeneca.com
  • Collapse
  • Expand
Copyright:
Copyright © 2023 by the National Comprehensive Cancer Network 2023
Article Category:
Abstract
Print Publication Date:
31 Mar 2023
Online Publication Date:
31 Mar 2023
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 86 86 28
PDF Downloads 0 0 0
EPUB Downloads 0 0 0